Table of Content

1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 MARKET SCOPE 24
1.3.1 MARKETS COVERED 24
FIGURE 1 NERVE REPAIR & REGENERATION MARKET SEGMENTATION 24
1.3.2 YEARS CONSIDERED FOR THE STUDY 25
1.4 CURRENCY 25
1.5 LIMITATIONS 25
1.6 STAKEHOLDERS 25
1.7 SUMMARY OF CHANGES MADE 26

2 RESEARCH METHODOLOGY 27
2.1 RESEARCH DATA 27
FIGURE 2 RESEARCH DESIGN 27
2.2 SECONDARY DATA 28
2.2.1 KEY DATA FROM SECONDARY SOURCES 28
2.3 PRIMARY DATA 28
2.3.1 KEY DATA FROM PRIMARY SOURCES 29
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 30
2.4 MARKET SIZE ESTIMATION 30
2.4.1 BOTTOM-UP APPROACH 30
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 30
2.4.2 GROWTH FORECAST 31
2.4.3 TOP-DOWN APPROACH 31
FIGURE 5 TOP-DOWN APPROACH 31
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 32
FIGURE 6 DATA TRIANGULATION METHODOLOGY 32
FIGURE 7 ASSUMPTIONS FOR THE STUDY 33

3 EXECUTIVE SUMMARY 34
FIGURE 8 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION) 34

4 PREMIUM INSIGHTS 39
4.1 NERVE REPAIR & REGENERATION MARKET OVERVIEW 39
4.2 NERVE REPAIR & REGENERATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 41
?

5 MARKET OVERVIEW 42
5.1 INTRODUCTION 42
5.2 MARKET DYNAMICS 42
FIGURE 19 NERVE REPAIR AND REGENERATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 42
5.2.1 DRIVERS 43
5.2.1.1 High incidence of nerve injuries 43
5.2.1.2 Rising geriatric population and subsequent growth in the prevalence of neurological disorders 43
5.2.1.3 Rising government support for neurologic disorder research 43
FIGURE 20 FUNDING FOR RESEARCH BY THE NIH, US 44
5.2.2 OPPORTUNITIES 45
5.2.2.1 Emerging markets 45
FIGURE 21 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS, 2012–2016 45
5.2.2.2 Potential of stem cell therapy in nerve repair and regeneration 45
5.2.2.3 Rising research in the field of neurology 46
FIGURE 22 RESEARCH PAPERS PUBLISHED (2011–2019) 46
TABLE 1 INDICATIVE LIST OF NEUROMODULATION CLINICAL TRAILS 46
5.2.3 CHALLENGES 47
5.2.3.1 Donor-site morbidity 47
5.2.3.2 Difficulties in treating large nerve gaps 47
5.2.3.3 Stringent regulatory frameworks and time-consuming approval processes 47
FIGURE 23 US FDA PRE-MARKET APPROVALS (2013–2018) 47
5.2.3.4 Greater preference for drug therapies over nerve repair and regeneration products 48
5.2.3.5 Dearth of trained professionals 48
5.2.3.6 Product recalls 48
TABLE 2 MAJOR PRODUCT RECALLS 48
5.3 IMPACT OF COVID-19 ON THE NERVE REPAIR AND REGENERATION MARKET 49

6 NERVE REPAIR AND REGENERATION MARKET, BY PRODUCT 50
6.1 INTRODUCTION 51
TABLE 3 NERVE REPAIR AND REGENERATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 51
6.2 NEUROSTIMULATION AND NEUROMODULATION DEVICES 51
TABLE 4 NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 51
TABLE 5 NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY REGION, 2018–2025 (USD MILLION) 52
6.2.1 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES 52
TABLE 6 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 52
TABLE 7 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018–2025 (USD MILLION) 53
6.2.1.1 Spinal cord stimulation devices 53
6.2.1.1.1 Increasing incidence of spinal cord injuries will support the growth of this product segment 53
TABLE 8 SPINAL CORD STIMULATION DEVICES MARKET, BY REGION,
2018–2025 (USD MILLION) 54
6.2.1.2 Deep brain stimulation devices 54
6.2.1.2.1 Increasing incidence of neurodegenerative diseases among the geriatric population will drive market growth 54
TABLE 9 DEEP BRAIN STIMULATION DEVICES MARKET, BY REGION,
2018–2025 (USD MILLION) 54
6.2.1.3 Vagus nerve stimulation devices 55
6.2.1.3.1 Increasing incidence of epilepsy to support market growth 55
TABLE 10 VAGUS NERVE STIMULATION DEVICES MARKET, BY REGION,
2018–2025 (USD MILLION) 55
6.2.1.4 Sacral nerve stimulation devices 55
6.2.1.4.1 Increasing incidence of urological disorders to drive market growth 55
TABLE 11 SACRAL NERVE STIMULATION DEVICES MARKET, BY REGION,
2018–2025 (USD MILLION) 56
6.2.1.5 Gastric electrical stimulation devices 56
6.2.1.5.1 GES is mainly used for the treatment of GERD and gastroparesis 56
TABLE 12 GASTRIC ELECTRICAL STIMULATION DEVICES MARKET, BY REGION,
2018–2025 (USD MILLION) 56
6.2.2 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES 57
TABLE 13 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 57
TABLE 14 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018–2025 (USD MILLION) 57
6.2.2.1 Transcutaneous electrical nerve stimulation devices 57
6.2.2.1.1 Extensive use in healthcare, low cost, and ease of use are supporting the growth of this segment 57
TABLE 15 TENS DEVICES MARKET, BY REGION, 2018–2025 (USD MILLION) 58
6.2.2.2 Transcranial magnetic stimulation devices 58
6.2.2.2.1 Minimal patient discomfort associated with TMS is supporting the adoption of TMS devices 58
TABLE 16 TMS DEVICES MARKET, BY REGION, 2018–2025 (USD MILLION) 59
6.2.2.3 Respiratory electric stimulation devices 59
6.2.2.3.1 Increasing incidence of spinal cord injuries to support market growth 59
TABLE 17 RES DEVICES MARKET, BY REGION, 2018–2025 (USD MILLION) 59
6.3 BIOMATERIALS 59
TABLE 18 BIOMATERIALS MARKET, BY TYPE, 2018–2025 (USD MILLION) 60
TABLE 19 BIOMATERIALS MARKET, BY REGION, 2018–2025 (USD MILLION) 60
?
6.3.1 NERVE CONDUITS 60
6.3.1.1 Increasing research in the field of nerve repair to support
market growth 60
TABLE 20 NERVE CONDUITS MARKET, BY REGION, 2018–2025 (USD MILLION) 61
6.3.2 NERVE WRAPS 61
6.3.2.1 Increasing incidence of peripheral injuries to drive market growth 61
TABLE 21 NERVE WRAPS MARKET, BY REGION, 2018–2025 (USD MILLION) 62

7 NERVE REPAIR AND REGENERATION MARKET, BY APPLICATION 63
7.1 INTRODUCTION 64
7.2 NEUROSTIMULATION & NEUROMODULATION APPLICATIONS 64
TABLE 22 NERVE REPAIR AND REGENERATION MARKET FOR NEUROSTIMULATION & NEUROMODULATION APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION) 64
TABLE 23 NERVE REPAIR AND REGENERATION MARKET FOR NEUROSTIMULATION & NEUROMODULATION APPLICATIONS, BY REGION,
2018–2025 (USD MILLION) 64
7.2.1 INTERNAL NEUROSTIMULATION & NEUROMODULATION 65
7.2.1.1 Minimally invasive nature and reversibility have supported
market growth 65
TABLE 24 INTERNAL NEUROSTIMULATION & NEUROMODULATION MARKET, BY REGION, 2018–2025 (USD MILLION) 65
7.2.2 EXTERNAL NEUROSTIMULATION & NEUROMODULATION 65
7.2.2.1 Non-invasive procedures have ensured high interest in this field 65
TABLE 25 EXTERNAL NEUROSTIMULATION & NEUROMODULATION MARKET,
BY REGION, 2018–2025 (USD MILLION) 65
7.3 NERVE REPAIR & REGENERATION BIOMATERIALS MARKET, BY APPLICATION 66
TABLE 26 NERVE REPAIR & REGENERATION BIOMATERIALS MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 66
7.3.1 DIRECT NERVE REPAIR/NEURORRHAPHY 66
TABLE 27 NERVE REPAIR AND REGENERATION BIOMATERIALS MARKET FOR DIRECT NERVE REPAIR/NEURORRHAPHY, BY TYPE, 2018–2025 (USD MILLION) 66
TABLE 28 NERVE REPAIR AND REGENERATION BIOMATERIALS MARKET FOR DIRECT NERVE REPAIR/NEURORRHAPHY, BY REGION, 2018–2025 (USD MILLION) 66
7.3.1.1 Epineural repair 67
7.3.1.1.1 Short operating times, ease, and minimal suturing requirements drive the demand for epineural repair 67
TABLE 29 EPINEURAL REPAIR MARKET, BY REGION, 2018–2025 (USD MILLION) 67
7.3.1.2 Perineural repair 67
7.3.1.2.1 Perineural repair is a highly complex surgery, which has affected its prospects in this market 67
TABLE 30 PERINEURAL REPAIR MARKET, BY REGION, 2018–2025 (USD MILLION) 67
7.3.1.3 Group fascicular repair 68
7.3.1.3.1 Group fascicular repair comes with a long procedural time 68
TABLE 31 GROUP FASCICULAR REPAIR MARKET, BY REGION,
2018–2025 (USD MILLION) 68
?
7.3.2 NERVE GRAFTING 68
TABLE 32 NERVE REPAIR AND REGENERATION BIOMATERIALS MARKET FOR NERVE GRAFTING, BY TYPE, 2018–2025 (USD MILLION) 68
TABLE 33 NERVE REPAIR AND REGENERATION BIOMATERIALS MARKET FOR NERVE GRAFTING, BY REGION, 2018–2025 (USD MILLION) 69
7.3.2.1 Autografts 69
7.3.2.1.1 Autografts are considered the gold standard for nerve gap treatment 69
FIGURE 24 ARTICLES PUBLISHED ON AUTOGRAFTS IN NERVE REPAIR, 2010–2018 69
TABLE 34 AUTOGRAFTS MARKET, BY REGION, 2018–2025 (USD MILLION) 70
7.3.2.2 Allografts 70
7.3.2.2.1 Advantages over autografts have driven market growth 70
FIGURE 25 ARTICLES PUBLISHED ON ALLOGRAFTS IN NERVE REPAIR, 2010–2018 70
TABLE 35 ALLOGRAFTS MARKET, BY REGION, 2018–2025 (USD MILLION) 71
7.3.2.3 Xenografts 71
7.3.2.3.1 Need for immunosuppression associated with xenograft use has restrained market growth 71
TABLE 36 XENOGRAFTS MARKET, BY REGION, 2018–2025 (USD MILLION) 71
7.3.3 STEM CELL THERAPY 71
7.3.3.1 Low penetration of stem cell therapy is counterbalanced by high growth prospects in the future 71
FIGURE 26 ARTICLES PUBLISHED ON STEM CELL THERAPY IN NERVE REPAIR,
2010–2018 72
TABLE 37 NERVE REPAIR AND REGENERATION BIOMATERIALS MARKET FOR STEM CELL THERAPY, BY REGION, 2018–2025 (USD MILLION) 72

8 NERVE REPAIR AND REGENERATION MARKET, BY REGION 73
8.1 INTRODUCTION 74
8.2 NORTH AMERICA 74
TABLE 39 NORTH AMERICA: NERVE REPAIR AND REGENERATION MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 76
TABLE 40 NORTH AMERICA: NERVE REPAIR AND REGENERATION MARKET,
BY PRODUCT, 2018–2025 (USD MILLION) 76
TABLE 41 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 76
TABLE 42 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 76
TABLE 43 NORTH AMERICA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 77
TABLE 44 NORTH AMERICA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 77
TABLE 45 NORTH AMERICA: BIOMATERIALS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 77
TABLE 46 NORTH AMERICA: BIOMATERIALS MARKET, BY TYPE,
2018–2025 (USD MILLION) 78
TABLE 47 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 78
TABLE 48 NORTH AMERICA: BIOMATERIALS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 78
8.2.1 US 78
8.2.1.1 High prevalence of neurological disorders to increase the demand for nerve repair and regeneration products in the US 78
TABLE 49 US: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 80
TABLE 50 US: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 80
TABLE 51 US: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 80
TABLE 52 US: BIOMATERIALS MARKET, BY TYPE, 2018–2025 (USD MILLION) 81
8.2.2 CANADA 81
8.2.2.1 Rising health expenditure and increasing disease prevalence will drive market growth 81
TABLE 54 CANADA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 82
TABLE 55 CANADA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 83
TABLE 56 CANADA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 83
TABLE 57 CANADA: BIOMATERIALS MARKET, BY TYPE, 2018–2025 (USD MILLION) 83
8.3 EUROPE 84
TABLE 58 EUROPE: NERVE REPAIR AND REGENERATION MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 84
TABLE 59 EUROPE: NERVE REPAIR AND REGENERATION MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 85
TABLE 60 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 85
TABLE 61 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 85
TABLE 62 EUROPE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 86
TABLE 63 EUROPE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 86
TABLE 64 EUROPE: BIOMATERIALS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 86
TABLE 66 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 87
8.3.1 GERMANY 87
8.3.1.1 Rising healthcare expenditure and favorable reimbursement policies ensure strong market growth 87
TABLE 68 GERMANY: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 88
TABLE 69 GERMANY: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 88
TABLE 70 GERMANY: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 89
TABLE 71 GERMANY: BIOMATERIALS MARKET, BY TYPE, 2018–2025 (USD MILLION) 89
8.3.2 UK 89
8.3.2.1 Government initiatives to drive the growth of the nerve repair and regeneration market in the UK 89
TABLE 72 UK: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 90
TABLE 73 UK: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 91
TABLE 74 UK: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 91
TABLE 75 UK: BIOMATERIALS MARKET, BY TYPE, 2018–2025 (USD MILLION) 91
8.3.3 FRANCE 92
8.3.3.1 Favorable healthcare reforms to support market growth in France 92
TABLE 76 FRANCE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 92
TABLE 77 FRANCE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 93
TABLE 78 FRANCE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 93
TABLE 79 FRANCE: BIOMATERIALS MARKET, BY TYPE, 2018–2025 (USD MILLION) 93
8.3.4 ITALY 94
8.3.4.1 Easy access to healthcare services has supported the use of market products 94
TABLE 80 ITALY: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 94
TABLE 81 ITALY: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 94
TABLE 82 ITALY: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 95
TABLE 83 ITALY: BIOMATERIALS MARKET, BY TYPE, 2018–2025 (USD MILLION) 95
8.3.5 SPAIN 95
8.3.5.1 Growing geriatric population and the subsequent increase in the incidence of neurological disorders to drive market growth in Spain 95
TABLE 84 SPAIN: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 96
TABLE 85 SPAIN: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 96
TABLE 86 SPAIN: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 96
TABLE 87 SPAIN: BIOMATERIALS MARKET, BY TYPE, 2018–2025 (USD MILLION) 97
8.3.6 REST OF EUROPE 97
TABLE 88 DEMENTIA PREVALENCE IN ROE COUNTRIES, 2018 VS. 2025 97
TABLE 89 PERCENTAGE OF POPULATION AGED 60 YEARS OR OVER, 2017 VS. 2050 98
TABLE 90 ROE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 98
TABLE 91 ROE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 98
TABLE 92 ROE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 99
TABLE 93 ROE: BIOMATERIALS MARKET, BY TYPE, 2018–2025 (USD MILLION) 99
8.4 ASIA PACIFIC 99
TABLE 94 APAC: NERVE REPAIR AND REGENERATION MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 101
TABLE 95 APAC: NERVE REPAIR AND REGENERATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 101
TABLE 96 APAC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 101
TABLE 97 APAC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 102
TABLE 98 APAC: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 102
TABLE 99 APAC: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 102
TABLE 102 APAC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY APPLICATION, 2018–2025 (USD MILLION) 103
8.4.1 JAPAN 104
8.4.1.1 Japan dominates the APAC market 104
TABLE 104 JAPAN: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 104
TABLE 105 JAPAN: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 105
TABLE 106 JAPAN: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 105
TABLE 107 JAPAN: BIOMATERIALS MARKET, BY TYPE, 2018–2025 (USD MILLION) 105
8.4.2 CHINA 106
8.4.2.1 Rising health expenditure and increased disease incidence will favor market growth 106
FIGURE 29 CHINA: CURRENT HEALTH EXPENDITURE, BY FINANCING SCHEME 106
TABLE 108 CHINA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 106
TABLE 109 CHINA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 107
TABLE 110 CHINA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 107
TABLE 111 CHINA: BIOMATERIALS MARKET, BY TYPE, 2018–2025 (USD MILLION) 107
8.4.3 INDIA 108
8.4.3.1 Changing government policies will have a positive impact on the market in India 108
TABLE 112 INDIA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 108
TABLE 113 INDIA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 109
TABLE 114 INDIA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 109
TABLE 115 INDIA: BIOMATERIALS MARKET, BY TYPE, 2018–2025 (USD MILLION) 109
8.4.4 REST OF ASIA PACIFIC (ROAPAC) 110
TABLE 116 ROAPAC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 110
TABLE 117 ROAPAC: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 111
TABLE 118 ROAPAC: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 111
TABLE 119 ROAPAC: BIOMATERIALS MARKET, BY TYPE, 2018–2025 (USD MILLION) 111
8.5 REST OF THE WORLD (ROW) 112
TABLE 120 ROW: NERVE REPAIR AND REGENERATION MARKET, BY REGION,
2018–2025 (USD MILLION) 112
TABLE 121 ROW: NERVE REPAIR AND REGENERATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 112
TABLE 122 ROW: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY REGION, 2018–2025 (USD MILLION) 113
TABLE 123 ROW: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 113
TABLE 124 ROW: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 113
TABLE 125 ROW: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 114
TABLE 126 ROW: BIOMATERIALS MARKET, BY REGION, 2018–2025 (USD MILLION) 114
TABLE 128 ROW: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET,
BY APPLICATION, 2018–2025 (USD MILLION) 114
FIGURE 30 POPULATION AGED 65 YEARS AND ABOVE (AS A PERCENTAGE OF THE
TOTAL POPULATION) 115
FIGURE 31 POPULATION OF PEOPLE AGED 65 YEARS AND ABOVE (MILLION) 116
TABLE 130 LATIN AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 116
TABLE 131 LATIN AMERICA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 116
TABLE 132 LATIN AMERICA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 117
TABLE 133 LATIN AMERICA: BIOMATERIALS MARKET, BY TYPE,
2018–2025 (USD MILLION) 117
TABLE 134 MIDDLE EAST & AFRICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 118
TABLE 135 MIDDLE EAST & AFRICA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 118
TABLE 136 MIDDLE EAST & AFRICA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 118
TABLE 137 MIDDLE EAST & AFRICA: BIOMATERIALS MARKET, BY TYPE,
2018–2025 (USD MILLION) 119
?

9 COMPETITIVE LANDSCAPE 120
9.1 OVERVIEW 120
FIGURE 32 PRODUCT LAUNCHES?THE MOST ADOPTED GROWTH STRATEGY FROM
2017 TO 2020 120
9.2 MARKET SHARE ANALYSIS, 2019 121
FIGURE 33 SHARES OF TOP COMPANIES IN THE GLOBAL NERVE REPAIR AND REGENERATION MARKET (2019) 121
9.3 COMPETITIVE SCENARIO 122
9.3.1 PRODUCT LAUNCHES AND APPROVALS 122
TABLE 138 KEY PRODUCT LAUNCHES AND APPROVALS, 2017–2020 122
9.3.2 PARTNERSHIPS, COLLABORATIONS, MERGERS, AND AGREEMENTS 123
TABLE 139 KEY PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS, 2017–2020 123
9.3.3 EXPANSIONS 123
TABLE 140 KEY EXPANSIONS, 2017–2020 123
9.3.4 ACQUISITIONS 124
TABLE 141 KEY ACQUISITIONS, 2017–2020 124
9.3.5 OTHER DEVELOPMENTS 124
TABLE 142 OTHER KEY DEVELOPMENTS, 2017–2020 124
9.4 COMPETITIVE LEADERSHIP MAPPING (2019) 125
9.4.1 VISIONARY LEADERS 125
9.4.2 INNOVATORS 125
9.4.3 DYNAMIC DIFFERENTIATORS 125
9.4.4 EMERGING COMPANIES 125
FIGURE 34 NERVE REPAIR AND REGENERATION MARKET: (GLOBAL) VENDOR COMPARISON MATRIX, 2019 126

10 COMPANY PROFILES 127
(Business overview, Products offered, Recent Developments, MNM view)*
10.1 MEDTRONIC, PLC. 127
FIGURE 35 MEDTRONIC: COMPANY SNAPSHOT (2019) 127
10.2 BOSTON SCIENTIFIC CORPORATION 130
FIGURE 36 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2019) 130
10.3 ABBOTT LABORATORIES 133
FIGURE 37 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019) 133
10.4 AXOGEN, INC. 135
FIGURE 38 AXOGEN: COMPANY SNAPSHOT (2019) 135
10.5 BAXTER INTERNATIONAL, INC. 137
FIGURE 39 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2019) 137
10.6 LIVANOVA, PLC. 139
FIGURE 40 LIVANOVA: COMPANY SNAPSHOT (2019) 139
10.7 INTEGRA LIFESCIENCES 141
FIGURE 41 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2019) 141
10.8 POLYGANICS 143
10.9 NEUROPACE, INC. 144
10.10 SOTERIX MEDICAL, INC. 145
10.11 NEVRO CORP. 146
FIGURE 42 NERVO CORP.: COMPANY SNAPSHOT (2019) 146
10.12 SYNAPSE BIOMEDICAL, INC. 148
10.13 ALEVA NEUROTHERAPEUTICS 149
10.14 COLLAGEN MATRIX, INC. 150
10.15 KERIMEDICAL 151
10.16 BIOWAVE CORPORATION 152
10.17 NEUROSIGMA 153
10.18 NEURONETICS, INC. 155
FIGURE 43 NEURONETICS: COMPANY SNAPSHOT (2019) 155
10.19 TVNS TECHNOLOGIES GMBH 157
10.20 GIMER MEDICAL 158
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

11 APPENDIX 159
11.1 INDUSTRY INSIGHTS 159
11.2 DISCUSSION GUIDE 160
11.3 KNOWLEDGE STORE 164
11.4 AVAILABLE CUSTOMIZATIONS 166
11.5 RELATED REPORTS 166
11.6 AUTHOR DETAILS 167